Carbocromen | CAS# 804-10-4 | coronary vasodilator agent

MedKoo Cat#: 412306 | Name: Carbocromen

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Carbocromen is a coronary vasodilator agent.

Chemical Structure

Carbocromen

CAS#804-10-4

Theoretical Analysis

MedKoo Cat#: 412306

Name: Carbocromen

CAS#: 804-10-4

Chemical Formula: C20H27NO5

Exact Mass: 361.1889

Molecular Weight: 361.44

Elemental Analysis: C, 66.46; H, 7.53; N, 3.88; O, 22.13

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Carbocromen; BRN1691147; BRN-1691147; BRN 1691147

IUPAC/Chemical Name

Acetic acid, ((3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy)-, ethyl ester

InChi Key

KLOIYEQEVSIOOO-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H27NO5/c1-5-21(6-2)11-10-17-14(4)16-9-8-15(12-18(16)26-20(17)23)25-13-19(22)24-7-3/h8-9,12H,5-7,10-11,13H2,1-4H3

SMILES Code

O=C(OCC)COC1=CC=C(C(O2)=C1)C(C)=C(CCN(CC)CC)C2=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 361.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Rodrigo-Armenteros P, Kapetanovic-García S, Antón-Méndez L, Gómez-Muga JJ, Río EB, Fernández-Cuesta MÁ, García-Moncó JC. Akinetic mutism and status epilepticus due to Epstein Barr virus encephalitis. Clin Neurol Neurosurg. 2019 Oct;185:105492. doi: 10.1016/j.clineuro.2019.105492. Epub 2019 Aug 19. PMID: 31470359. 2: Hensel JM, Shaw J, Ivers NM, Desveaux L, Vigod SN, Cohen A, Onabajo N, Agarwal P, Mukerji G, Yang R, Nguyen M, Bouck Z, Wong I, Jeffs L, Jamieson T, Bhatia RS. A Web-Based Mental Health Platform for Individuals Seeking Specialized Mental Health Care Services: Multicenter Pragmatic Randomized Controlled Trial. J Med Internet Res. 2019 Jun 4;21(6):e10838. doi: 10.2196/10838. PMID: 31165710; PMCID: PMC6684216. 3: Cacioppo S, Cacioppo JT. Dynamic spatiotemporal brain analyses using high- performance electrical neuroimaging, Part II: A step-by-step tutorial. J Neurosci Methods. 2015 Dec 30;256:184-97. doi: 10.1016/j.jneumeth.2015.09.004. Epub 2015 Sep 10. PMID: 26363189. 4: Quezada E, Delogu G, Picciau C, Santana L, Podda G, Borges F, García-Morales V, Viña D, Orallo F. Synthesis and vasorelaxant and platelet antiaggregatory activities of a new series of 6-halo-3-phenylcoumarins. Molecules. 2010 Jan 12;15(1):270-9. doi: 10.3390/molecules15010270. PMID: 20110890; PMCID: PMC6257048. 5: Bucolo C, Ward KW, Mazzon E, Cuzzocrea S, Drago F. Protective effects of a coumarin derivative in diabetic rats. Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3846-52. doi: 10.1167/iovs.08-3328. Epub 2009 Mar 11. PMID: 19279317. 6: Bucolo C, Maugeri F, Maltese A, Ward KW. Retinal and systemic pharmacokinetics of the anti-inflammatory drug cloricromene following oral administration in the rat and rabbit. J Ocul Pharmacol Ther. 2007 Jun;23(3):257-63. doi: 10.1089/jop.2006.141. PMID: 17593009. 7: Pignatello R, Maltese A, Maugeri F, Bucolo C. Enhancement of availability of cloricromene at brain level by a lipophilic prodrug. J Pharm Pharmacol. 2006 Jul;58(7):1001-5. doi: 10.1211/jpp.58.7.0017. PMID: 16805962. 8: Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G. Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech. 2006 Mar 24;7(1):E27. doi: 10.1208/pt070127. PMID: 16584158; PMCID: PMC2750734. 9: Muià C, Mazzon E, Zito D, Maiere D, Britti D, Crisafulli C, Oteri G, Cordasco G, Cuzzocrea S. Cloricromene, a coumarine derivative, reduced the development of periodontitis in rats. Naunyn Schmiedebergs Arch Pharmacol. 2006 Apr;373(1):51-9. doi: 10.1007/s00210-006-0048-3. Epub 2006 Mar 28. PMID: 16572308. 10: Ragazzi E, Costa CV, Comai S, Bertazzo A, Caparrotta L, Allegri G. Cloricromene effect on the enzyme activities of the tryptophan-nicotinic acid pathway in diabetic/hyperlipidemic rabbits. Life Sci. 2006 Jan 18;78(8):785-94. doi: 10.1016/j.lfs.2005.05.077. Epub 2005 Aug 26. PMID: 16126232. 11: Ianaro A, Maffia P, Grassia G, Di Meglio P, Sorrentino R, di Villa Bianca Rd, Di Rosa M, Ialenti A. Cloricromene in endotoxemia: role of NF-kappaB. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):140-5. doi: 10.1007/s00210-004-0956-z. Epub 2004 Jul 30. PMID: 15322736. 12: Bucolo C, Maltese A, Maugeri F, Busà B, Puglisi G, Pignatello R. Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. J Pharm Pharmacol. 2004 Jul;56(7):841-6. doi: 10.1211/0022357023835. PMID: 15233861. 13: Leo E, Brina B, Forni F, Vandelli MA. In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. Int J Pharm. 2004 Jun 18;278(1):133-41. doi: 10.1016/j.ijpharm.2004.03.002. PMID: 15158956. 14: Fries W, Mazzon E, Sturiale S, Giofré MR, Lo Presti MA, Cuzzocrea S, Campo GM, Caputi AP, Longo G, Sturniolo GC. A protective effect of the synthetic coumarine derivative Cloricromene against DNB-colitis in the rat. Life Sci. 2004 Apr 16;74(22):2749-56. doi: 10.1016/j.lfs.2003.10.016. PMID: 15043989. 15: Bondì ML, Fontana G, Carlisi B, Giammona G. Preparation and characterization of solid lipid nanoparticles containing cloricromene. Drug Deliv. 2003 Oct- Dec;10(4):245-50. doi: 10.1080/drd_10_4_245. PMID: 14612340. 16: Bucolo C, Cuzzocrea S, Mazzon E, Caputi AP. Effects of cloricromene, a coumarin derivative, on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1178-84. doi: 10.1167/iovs.02-0559. PMID: 12601047. 17: Maltese A, Bucolo C. Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Feb 5;767(1):153-8. doi: 10.1016/s1570-0232(01)00567-0. PMID: 11863286. 18: Savastano M, Tomaselli F, Maggiori S. Intradermal injection vs. oral treatment of tinnitus. Therapie. 2001 Jul-Aug;56(4):403-7. PMID: 11677863. 19: Rouleau JR, Dagnault A, Simard D, Lavallée B, Bélanger A, Blouin A, Kingma JG Jr. Effect of estrogen replacement therapy on distribution of myocardial blood flow in female anesthetized rabbits. Am J Physiol Heart Circ Physiol. 2001 Sep;281(3):H1407-12. doi: 10.1152/ajpheart.2001.281.3.H1407. PMID: 11514313. 20: Corsini E, Lucchi L, Binaglia M, Viviani B, Bevilacqua C, Monastra G, Marinovich M, Galli CL. Cloricromene, a semi-synthetic coumarin derivative, inhibits tumor necrosis factor-alpha production at a pre-transcriptional level. Eur J Pharmacol. 2001 Apr 27;418(3):231-7. doi: 10.1016/s0014-2999(01)00910-4. PMID: 11343695.